PACB — Pacific Biosciences of California, Inc.

Summary of PacBio Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 Revenue: $44.6 million, a 14% increase year-over-year and a 16% increase quarter-over-quarter.
• Full Year Revenue: $160 million, representing 4% growth over 2024.
• Consumables Revenue: Grew 15% year-over-year in Q4, reaching a record of $21.6 million; full year consumables revenue increased 16% to $82 million.
• Instrument Revenue: Increased 13% in Q4 to $17.3 million, but decreased 18% for the full year to $53.8 million.
• Non-GAAP Gross Margin: Improved to 40% in Q4 from 31% in Q4 2024; full year gross margin also at 40%, up from 33% in 2024.
• Non-GAAP Operating Expenses: Reduced to $56.2 million in Q4 from $68.6 million in Q4 2024; full year expenses down to $229.9 million from $289.2 million in 2024.
• Cash Position: Ended 2025 with approximately $280 million in cash and investments.

2. Strategic Updates and Business Highlights:

• Instrument Placements: Shipped 21 Revio and 42 Vega systems in Q4, with cumulative shipments of 331 Revio and 147 Vega systems.
• Clinical Market Growth: Significant traction in clinical applications, particularly in rare disease and oncology, with 55% growth in consumables for clinical customers in 2025.
• New Product Launch: SPRQ-Nx, a next-generation consumable chemistry, expected to lower costs and improve gross margins, with a broad launch anticipated in 2026.
• Focus on Long-Read Sequencing: Continued emphasis on expanding the HiFi sequencing technology in clinical settings, supported by partnerships and initiatives in rare disease genomics.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $165 million and $180 million, representing approximately 8% growth at the midpoint.
• Gross Margin Improvement: Anticipated increase of 100 to 400 basis points in non-GAAP gross margin in 2026, driven by higher consumables mix and the introduction of SPRQ-Nx.
• Operating Expenses: Expected to slightly improve compared to 2025 levels, with a focus on disciplined spending and investment in next-generation sequencing.

4. Bad News, Challenges, or Points of Concern:

• Academic Funding Environment: Continued pressure on instrument sales due to a challenging academic funding landscape, with no significant recovery anticipated.
• Instrument Revenue Decline: Notable decrease in instrument revenue for the full year, primarily due to lower Revio shipments.
• Component Cost Volatility: Potential headwinds from volatility in component costs, particularly memory costs, impacting gross margins.
• Limited Budget Flush: Minimal opportunistic purchasing observed at the end of Q4, indicating cautious spending behavior among customers.

5. Notable Q&A Insights:

• Revio Pull-Through: Expected to remain stable, with SPRQ-Nx potentially increasing utilization without significantly altering pull-through metrics.
• International Growth: Strong clinical growth anticipated in EMEA, with a cautious outlook for U.S. clinical growth driven by targeted sequencing panels.
• Multisystem Orders: While expected to become more common, the impact on ASP due to discounts remains uncertain; the focus is on maximizing lifetime customer value.
• Cost Management: Continued efforts to reduce operating expenses while investing in critical R&D programs and managing G&A expenses effectively.

Overall, PacBio demonstrated strong growth in consumables and improved financial metrics, but faces challenges in instrument sales and external funding environments. The company is optimistic about future growth driven by new product launches and clinical adoption of its sequencing technologies.